Colchicine as an Adjuvant Therapy for Coronary Artery Disease

Abstract

Introduction Colchicine, a potent anti-inflammatory agent, is being explored as an adjuvant therapy for coronary artery disease (CAD), but its clinical utility is debated due to conflicting trial evidence. This literature review synthesizes recent findings from meta-analyses to evaluate the efficacy and safety of colchicine in managing CAD.

Methods This review analyzes five systematic reviews and meta-analyses published between 2021 and 2023. The analysis examines colchicine's efficacy in acute and chronic coronary syndromes. The focus is on its impact on inflammatory markers, major adverse cardiovascular events (MACE), and its safety profile.

Results The evidence is mixed. While some analyses found no significant impact on high-sensitivity C-reactive protein (hs-CRP) levels , others showed significant cardiovascular benefits. Low-dose colchicine was found to reduce MACE, including myocardial infarction, especially when initiated early after an acute event. However, some trials reported no significant benefit, highlighting conflicting outcomes. The primary adverse effects were gastrointestinal.

Discussion The conflicting results suggest colchicine's efficacy is context-dependent. Factors like timing of administration and patient selection are critical determinants of its benefit. The discrepancy between observed clinical benefits and inconsistent effects on hs-CRP suggests its mechanism may be more complex than systemic inflammation reduction alone.

Conclusion Colchicine shows promise as an adjuvant therapy for secondary prevention in CAD. However, inconsistent findings and known gastrointestinal side effects mean its role is not fully established. Further research is needed to define optimal patient selection, timing, and long-term safety before its widespread clinical integration.